华神科技：子公司星瑞药业以2亿元出售上海凌凯5.4019%股份

Group 1 - The core point of the article is that Huasheng Technology (000790) announced the transfer of 5.4019% shares of Shanghai Lingkai held by its subsidiary Xingrui Pharmaceutical for 200 million yuan, after which Xingrui Pharmaceutical will no longer hold any shares in Shanghai Lingkai [1] Group 2 - The transaction indicates a strategic decision by Huasheng Technology to divest its stake in Shanghai Lingkai, potentially reallocating resources or focusing on other investments [1] - The completion of this transaction marks a significant change in the ownership structure of Shanghai Lingkai, as Xingrui Pharmaceutical exits its investment [1] - The financial implications of this transfer could affect Huasheng Technology's balance sheet and future investment strategies [1]